SynCore Bio Doses First Patient In Phase III Trial for SB05 Pancreatic Cancer in South Korea
Taipei, Taiwan, 25 December 2018. SynCore Biotechnology Co. (4192:TT) [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer in Israel
SB05 (EndoTAG®-1) is approved to conduct [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer in Russia
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial [...]
SynCore Biotechnology has Received the Approval to Conduct SB05 PC for Phase III Clinical Trial in South Korea
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial in [...]
SB05 PC for Pancreatic Cancer is Approved to implement Phase III Clinical Trial in Hungary
SynCore Biotechnology has received the approval from OGYEI to [...]
2018 Symposium on Research Development in Dry Age-Related Macular Degeneration
2018 Symposium on Research Development in Dry Age-Related Macular [...]
SynCoreBio to Participate China BioMed Innovation and Investment Conference and Bio-partnering APAC on September 18-21
SynCore Biotechnology announced that the company will attend the [...]
SynCore Bio Signs Agreement with British Company Epipole to Distribute Eye Disease Diagnosis Fundus Cameras in Taiwan
SynCore Biotechnology Co. Ltd. (4192) signed an international contract [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer by ANSM
We are excited to announce that SynCore Biotechnology receives [...]
SynCore Biotechnology to attend at 2018 BIO International Convention in Boston, MA
SynCore Biotechnology (SynCoreBio) is pleased to announce that it [...]